Chemomab TherapeuticsCMMB
13F holders, Q4 2024 (December 31)16holders +1
4new positions
4sold out
$1.81avg. 13F price*
At the end of Q4 2024, 16 institutions reported holding Chemomab Therapeutics Ltd. (CMMB) in their 13F filings, up 1 from Q3 2024. 4 opened new positions and 4 sold out. The largest holders were Orbimed Advisors LLC ($3.2M), Sphera Funds Management LTD. ($2.2M) and Yelin Lapidot Holdings Management Ltd. ($1.3M).
- Company
- Chemomab Therapeutics Ltd.
- CUSIP
- 16385C104
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $65K |
| Exits | 4 | $102K |
All 13F filers, Q3 2024 → Q4 2024: 45,750 shares bought and 434,894 shares sold, net −389,144 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Orbimed Advisors LLC | 0.07% | No change | 1,741,273 | $3.2M |
| Sphera Funds Management LTD. | 0.41% | No change | 1,214,575 | $2.2M |
| Yelin Lapidot Holdings Management Ltd. | 0.23% | Reduce -8.1% | 744,127 | $1.3M |
| Ikarian Capital, LLC | 0.11% | Reduce -0.2% | 213,052 | $386K |
| Morgan Stanley | 0.00% | Reduce -74.0% | 104,400 | $189K |
| Kestra Private Wealth Services, LLC | 0.00% | No change | 31,241 | $57K |
| Boothbay Fund Management, LLC | 0.00% | Reduce -1.3% | 26,189 | $47K |
| XTX Topco Ltd | 0.00% | Add +63.8% | 24,929 | $45K |
| Rhumbline Advisers | 0.00% | Reduce -13.7% | 23,808 | $43K |
| Virtu Financial LLC | 0.00% | New | 14,445 | $26K |
| Wetzel Investment Advisors, Inc. | 0.01% | New | 10,000 | $18K |
| BNP Paribas Financial Markets | 0.00% | New | 6,500 | $12K |
| GAMMA Investing LLC | 0.00% | New | 5,099 | $9K |
| Moser Wealth Advisors, LLC | 0.00% | No change | 500 | $905 |
| UBS Group AG | 0.00% | Reduce -78.8% | 485 | $878 |
| SBI Securities Co., Ltd. | 0.00% | — | 100 | $181 |
"% of holder's portfolio" is CMMB's weight in each manager's 13F, not the share of Chemomab Therapeutics Ltd. the manager owns.